JP2022500364A5 - - Google Patents

Info

Publication number
JP2022500364A5
JP2022500364A5 JP2021511641A JP2021511641A JP2022500364A5 JP 2022500364 A5 JP2022500364 A5 JP 2022500364A5 JP 2021511641 A JP2021511641 A JP 2021511641A JP 2021511641 A JP2021511641 A JP 2021511641A JP 2022500364 A5 JP2022500364 A5 JP 2022500364A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
μmol
use according
per
total amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021511641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500364A (ja
JP7634476B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/051247 external-priority patent/WO2020056399A1/en
Publication of JP2022500364A publication Critical patent/JP2022500364A/ja
Publication of JP2022500364A5 publication Critical patent/JP2022500364A5/ja
Application granted granted Critical
Publication of JP7634476B2 publication Critical patent/JP7634476B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021511641A 2018-09-16 2019-09-16 関節への送達に適した医薬組成物及びその関節痛の治療における使用 Active JP7634476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16
US62/731,941 2018-09-16
PCT/US2019/051247 WO2020056399A1 (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Publications (3)

Publication Number Publication Date
JP2022500364A JP2022500364A (ja) 2022-01-04
JP2022500364A5 true JP2022500364A5 (enExample) 2024-07-22
JP7634476B2 JP7634476B2 (ja) 2025-02-21

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021511641A Active JP7634476B2 (ja) 2018-09-16 2019-09-16 関節への送達に適した医薬組成物及びその関節痛の治療における使用

Country Status (15)

Country Link
US (1) US12208104B2 (enExample)
EP (1) EP3849522A1 (enExample)
JP (1) JP7634476B2 (enExample)
KR (1) KR20210060559A (enExample)
CN (1) CN112702993A (enExample)
AU (1) AU2019339528B2 (enExample)
BR (1) BR112021004880A2 (enExample)
CA (1) CA3112234A1 (enExample)
CL (1) CL2021000627A1 (enExample)
IL (1) IL281513B1 (enExample)
MX (1) MX2021003030A (enExample)
SG (1) SG11202102400PA (enExample)
TW (1) TWI843751B (enExample)
WO (1) WO2020056399A1 (enExample)
ZA (1) ZA202101688B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537474A (ja) 2020-08-05 2023-09-01 ティーエルシー バイオファーマシューティカルズ、インク. 疼痛制御のための関節内コルチコステロイドの医薬組成物
EP4706666A1 (en) * 2023-05-05 2026-03-11 Xiangya Hospital, Central South University Use of magnesium hydroxide in preparation of drug for treating arthralgia
IL327816A (en) * 2023-11-03 2026-06-01 Taiwan Liposome Co Ltd Liposomal composition of intra-articular corticosteroid for pain control

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
AU2013216861B2 (en) 2012-02-10 2017-05-18 Tlc Biopharmaceuticals, Inc Pharmaceutical compositions to reduce complications of ocular steroid
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite

Similar Documents

Publication Publication Date Title
Tamm et al. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice
JP2006527193A5 (enExample)
US7691811B2 (en) Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US20200253871A1 (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
JP2022523548A5 (enExample)
US20170281648A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
DE03754425T1 (de) Anwendungen die in Bezug stehen mit durch Wasser stabilisierte medizinische Aerosolformulierungen
Goldsmith et al. Budesonide/formoterol: a review of its use in asthma
US20140329782A1 (en) Combined therapeutic agent
JP2023546361A5 (enExample)
MX2007001567A (es) Medicamentos para tratar enfermedad respiratoria cronica.
JP2007505829A5 (enExample)
Boulet Once-daily inhaled corticosteroids for the treatment of asthma
JP2016128504A (ja) 筋ジストロフィーの治療に用いられるジエチル−[6−(4−ヒドロキシカルバモイル−フェニル−カルバモイルオキシ−メチル)−ナフタレン−2−イル−メチル]−アンモニウムクロリド
RU2021109952A (ru) Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли
Vastagh et al. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC
CN1306429A (zh) 糖皮质类固醇在制备治疗轻度/早期c opd(慢性阻塞性肺病)的药物中的应用
Kuhn Immunoglobulin E blockade in the treatment of asthma
Colice New developments in inhaled corticosteroids
Masekela et al. Asthma treatment in children: A pragmatic approach
JP2023537474A5 (enExample)
Zöllner Is adrenal suppression in asthmatic children reversible? A case series
RU2021102859A (ru) Способы уменьшения осложнений от внутрисуставного стероида
JP5220741B2 (ja) アンドラスト/グルココルチコイドの併用
JP2007533706A5 (enExample)